Figure 9.

Construction of prognostic model for exosomal miR-425-5p in BC patients. (a) Exosome from blood of BC patient identification by TEM. (b) Size distribution of MDA-MB-231- and BT549-derived exosome diameters. (c) Detection of TSG101 and HSP70 protein expression by western blot. (d) The mRNA level of miR-425-5p was detected in exosomes from blood between healthy donors and BC patients. (e) Kaplan-Meier survival analysis for miR-425-5p expression in exosomes from blood of BC patients. (f, g) LASSO Cox analysis identified 4 factors correlated with the overall survival. (h) The ROC curve showed that the AUC of the 4-factors prognostic model was 0.835. (i) Risk score distribution, survival overview, and the heatmap showing the expression profiles of miR-425-5p from exosomes in the high- and low-risk groups. (j) The patients in the high-risk group exhibited a worse overall survival than those in the low-risk group. (k) Independent prognostic analysis showed that the 4-factor risk signature was significantly correlated with the OS of BC patients by a univariate Cox regression analysis. (l) Independent prognostic analysis showed that the 4-factor risk signature was significantly correlated with the OS of BC patients by a multivariate Cox regression analysis. (m) The nomogram of risk score and clinical characteristics. LASSO: least absolute shrinkage and selection operator; ROC: receiver operating characteristic; AUC: area under curve; OS: overall survival. Experimental data presented as means ± standard deviation. Experiment was repeated 3 times. ^∗∗P < 0.01 compared with the normal group.